Anti-VEGF
EC approves use of Eylea 8mg for extended treatment intervals
The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8mg (aflibercept 8mg, 114.3mg/ml...
Read moreDetails
Gene therapy could replace current nAMD treatments
A single-dose gene therapy for neovascular age-related macular degeneration (nAMD) is now in Phase 3 clinical trials and, if approved,...
Read moreDetails
Newly approved high dose aflibercept tipped to reach ‘blockbuster’ status
Bayer’s high dose aflibercept 8 mg – now approved in the European Union and US – has been labelled...
Read moreDetails